$EXOZ News

eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

EXoZymes Inc (EXOZ) (Q2 2026) Earnings Call Highlights: Strategic Pivot and 10x Productivity ...

eXoZymes Q2 Earnings Call Highlights

eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today

eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets

eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026

eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing

eXoZymes Selected To Participate In Inaugural U.S. DOE Genesis Mission; Co. To Collaborate With Lawrence Berkeley National Laboratory On AI-Enabled Digital Twins For Cell-Free Biomanufacturing

eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery

eXoZymes Wins $2M NIH Grant To Advance Cannabinoid Analogs For Drug Discovery

eXoZymes Inc. Announces Closing of $6 Million Public Offering

eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants

eXoZymes Prices ~$5.33M Offering Of Units At $18/Unit

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program

EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

eXoZymes Q4 Earnings Call Highlights

eXoZymes Provides Fourth Quarter and Full Year 2025 Update

eXoZymes Inc. - Common Stock Q4 EPS $(0.31)

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026